Sanofi announces U.S. availability of Soliqua 100/33

PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 

 

Sanofi said the daily wholesale acquisition price of Soliqua 100/33 was $127 for a 300 mL pen, an average of about $19.90 per day given the average final dose of 47 mL used in clinical trials. It is also offering it at a $0 for eligible patients with commercial insurance and is working on securing coverage on nationwide health plans. It will also offer Soliqua 100/33 COACH, for patients who have been prescribed the medication. 

 

“By offering Soliqua 100/33 – a product containing both a basal insulin and a GLP-1 therapy — at a competitive price while facilitating patient access, we believe we are providing value to patients and the healthcare system,” Sanofi EVP and head of its global diabetes and cardiovascular business unit Peter Guenter said.